CCN2: a bona fide target for anti-fibrotic drug intervention |
| |
Authors: | Andrew Leask |
| |
Affiliation: | Departments of Dentistry and Physiology and Pharmacology, University of Western Ontario, London, ON Canada N6A 5C1 |
| |
Abstract: | CCN2 (formerly known as connective tissue growth factor) was identified by several different laboratories approximately 20 years ago. Almost since its identification as a factor induced in normal fibroblasts by transforming growth factor β and overexpressed in fibrotic disease, CCN2 has been hypothesized to be not only a marker but also a central mediator of fibrosis in vivo. Finally, in vivo data are emerging to validate this key hypothesis. For example, a neutralizing anti-CCN2 antibody was found to attenuate fibrogenesis in three separate animal models (Wang et al. in Fibrogenesis Tissue Repair 4:1–4, 2011). This commentary addresses recent data indicating that CCN2 appears to represent a key central mediator of fibrosis and a good target for anti-fibrotic drug intervention. |
| |
Keywords: | Ctgf ccn2 Fibrosis Bleomycin UUO Conditional knockout |
本文献已被 PubMed SpringerLink 等数据库收录! |
|